Literature DB >> 18316373

Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors.

William J Valentine1, James I Fells, Donna H Perygin, Sana Mujahid, Kazuaki Yokoyama, Yuko Fujiwara, Ryoko Tsukahara, James R Van Brocklyn, Abby L Parrill, Gabor Tigyi.   

Abstract

Lysophosphatidic acid (LPA) is a ligand for three endothelial differentiation gene family G protein-coupled receptors, LPA(1-3). We performed computational modeling-guided mutagenesis of conserved residues in transmembrane domains 3, 4, 5, and 7 of LPA(1-3) predicted to interact with the glycerophosphate motif of LPA C18:1. The mutants were expressed in RH7777 cells, and the efficacy (E(max)) and potency (EC(50)) of LPA-elicited Ca(2+) transients were measured. Mutation to alanine of R3.28 universally decreased both the efficacy and potency in LPA(1-3) and eliminated strong ionic interactions in the modeled LPA complexes. The alanine mutation at Q3.29 decreased modeled interactions and activation in LPA(1) and LPA(2) more than in LPA(3). The mutation W4.64A had no effect on activation and modeled LPA interaction of LPA(1) and LPA(2) but reduced the activation and modeled interactions of LPA(3). The R5.38A mutant of LPA(2) and R5.38N mutant of LPA(3) showed diminished activation by LPA; however, in LPA(1) the D5.38A mutation did not, and mutation to arginine enhanced receptor activation. In LPA(2), K7.36A decreased the potency of LPA; in LPA(1) this same mutation increased the E(max). In LPA(3), R7.36A had almost no effect on receptor activation; however, the mutation K7.35A increased the EC(50) in response to LPA 10-fold. In LPA(1-3), the mutation Q3.29E caused a modest increase in EC(50) in response to LPA but caused the LPA receptors to become more responsive to sphingosine 1-phosphate (S1P). Surprisingly micromolar concentrations of S1P activated the wild type LPA(2) and LPA(3) receptors, indicating that S1P may function as a weak agonist of endothelial differentiation gene family LPA receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316373      PMCID: PMC3774115          DOI: 10.1074/jbc.M708847200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Structural features of EDG1 receptor-ligand complexes revealed by computational modeling and mutagenesis.

Authors:  A L Parrill; D L Baker; D A Wang; D J Fischer; D L Bautista; J Van Brocklyn; S Spiegel; G Tigyi
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

Review 2.  International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Edward J Goetzl; Timothy Hla; Yasuyuki Igarashi; Kevin R Lynch; Wouter Moolenaar; Susan Pyne; Gabor Tigyi
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

3.  Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.

Authors:  D J Fischer; N Nusser; T Virag; K Yokoyama; D L Baker; D Bautista; A L Parrill; G Tigyi
Journal:  Mol Pharmacol       Date:  2001-10       Impact factor: 4.436

4.  Enhancement of the migration of metastatic human breast cancer cells by phosphatidic acid.

Authors:  D Sliva; R Mason; H Xiao; D English
Journal:  Biochem Biophys Res Commun       Date:  2000-02-16       Impact factor: 3.575

5.  Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate.

Authors:  D S Im; C E Heise; M A Harding; S R George; B F O'Dowd; D Theodorescu; K R Lynch
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

6.  Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor.

Authors:  M H Rhee; I Nevo; M L Bayewitch; O Zagoory; Z Vogel
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

7.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.

Authors:  B M Schwartz; G Hong; B H Morrison; W Wu; L M Baudhuin; Y J Xiao; S C Mok; Y Xu
Journal:  Gynecol Oncol       Date:  2001-05       Impact factor: 5.482

8.  Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid.

Authors:  S An; T Bleu; O G Hallmark; E J Goetzl
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

9.  A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors.

Authors:  D A Wang; Z Lorincz; D L Bautista; K Liliom; G Tigyi; A L Parrill
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

Review 10.  Lysophospholipids and the cardiovascular system.

Authors:  Joel S Karliner
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  21 in total

1.  Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity.

Authors:  Sung Hee Hwang; Tae-Joon Shin; Sun-Hye Choi; Hee-Jung Cho; Byung-Hwan Lee; Mi Kyung Pyo; Jun-Ho Lee; Jiyeon Kang; Hyeon-Joong Kim; Chan-Woo Park; Ho-Chul Shin; Seung-Yeol Nah
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

Review 2.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

Review 3.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

Review 4.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

5.  FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.

Authors:  William J Valentine; Virginia I Godwin; Daniel A Osborne; Jianxiong Liu; Yuko Fujiwara; James Van Brocklyn; Robert Bittman; Abby L Parrill; Gabor Tigyi
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

Review 6.  Comparative analyses of lysophosphatidic acid receptor-mediated signaling.

Authors:  Nobuyuki Fukushima; Shoichi Ishii; Toshifumi Tsujiuchi; Nao Kagawa; Kazutaka Katoh
Journal:  Cell Mol Life Sci       Date:  2015-03-04       Impact factor: 9.261

Review 7.  Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity.

Authors:  Steve N Georas
Journal:  Immunol Res       Date:  2009-01-30       Impact factor: 2.829

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Authors:  Gyöngyi N Kiss; James I Fells; Renuka Gupte; Sue-Chin Lee; Jianxiong Liu; Nóra Nusser; Keng G Lim; Ramesh M Ray; Fang-Tsyr Lin; Abby L Parrill; Balázs Sümegi; Duane D Miller; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2012-09-11       Impact factor: 4.436

Review 10.  Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.

Authors:  Abby L Parrill; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.